Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in Overweight or Obesity
NCT07357766Phase 3Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 14
01
Overview
A Phase 3 trial of CagriSema in obesity, sponsored by Novo Nordisk. Planned start Jun 2026; status: withdrawn.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07357766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07357766.